- Home
- DECK vs GH Comparison
DECK vs GH Comparison
Compare DECK & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DECK | GH |
|---|---|---|
| Founded | 1973 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Shoe Manufacturing | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.0B | 13.3B |
| IPO Year | 1996 | 2018 |
Fundamental Metrics
Financial Performance| Metric | DECK | GH |
|---|---|---|
| Price | $109.93 | $90.72 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 23 | 19 |
| Target Price | ★ $122.45 | $119.79 |
| AVG Volume (30 Days) | 1.8M | ★ 2.1M |
| Earning Date | 05-21-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 6.74 |
| EPS | ★ 6.04 | N/A |
| Revenue | ★ $4,985,612,000.00 | $982,021,000.00 |
| Revenue This Year | $11.16 | $33.30 |
| Revenue Next Year | $6.96 | $28.27 |
| P/E Ratio | $18.60 | ★ N/A |
| Revenue Growth | 16.28 | ★ 32.88 |
| 52 Week Low | $78.91 | $36.36 |
| 52 Week High | $131.58 | $120.74 |
Technical Indicators
Market Signals| Indicator | DECK | GH |
|---|---|---|
| Relative Strength Index (RSI) | 57.97 | 52.59 |
| Support Level | $96.20 | $89.32 |
| Resistance Level | $121.04 | $101.77 |
| Average True Range (ATR) | 3.51 | 5.54 |
| MACD | 1.28 | 0.60 |
| Stochastic Oscillator | 78.21 | 66.89 |
Price Performance
Historical ComparisonAbout DECK Deckers Outdoor Corporation
Founded in 1973, California-based Deckers designs and sells casual and performance footwear, apparel, and accessories. In fiscal 2025, Ugg and Hoka accounted for 51% and 45% of total sales, respectively. The firm also markets a niche sandal brand called Teva. Deckers produces most of its sales through wholesale partnerships but also operates e-commerce in more than 50 countries and has more than 200 company-operated stores. It generated 64% of its fiscal 2025 sales in the United States.
About GH Guardant Health Inc.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.